Cargando…

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer

BACKGROUND: The investigational use of zolbetuximab (IMAB362), a groundbreaking monoclonal antibody medication targeting claudin 18.2 (CLDN18.2), for treatment of advanced gastrointestinal cancers is currently underway. The unclear clinicopathological characteristics and tumour immune microenvironme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Canming, Wang, Yukai, Chen, Jinxia, Wang, Yi, Pang, Chuhong, Liang, Chen, Yuan, Li, Ma, Yubo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428652/ https://www.ncbi.nlm.nih.gov/pubmed/37582713 http://dx.doi.org/10.1186/s12876-023-02924-y

Ejemplares similares

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
por: Chen, Jinxia, et al.
Publicado: (2023)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”
por: Li, Cuicui, et al.
Publicado: (2023)

ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
por: Konno, Hiroyasu, et al.
Publicado: (2022)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
por: Gao, Peipei, et al.
Publicado: (2021)

Analysis of the expression and genetic alteration of CLDN18 in gastric cancer
por: Li, Jian, et al.
Publicado: (2020)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer
por: Rao, XiongHui, et al.
Publicado: (2021)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
por: Nakayama, Izuma, et al.
Publicado: (2019)

Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer
por: Shu, Yang, et al.
Publicado: (2018)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis
por: Gao, Fangmei, et al.
Publicado: (2019)

The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Wei-Han, et al.
Publicado: (2020)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer
por: Matsusaka, Keisuke, et al.
Publicado: (2016)

Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Construction and validation of a prognosis signature based on the immune microenvironment in gastric cancer
por: Wu, Li-Hong, et al.
Publicado: (2023)

CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis
por: Han, Lu, et al.
Publicado: (2023)

Membranous and nuclear staining of CLDN18 in HPV‐independent and HPV‐associated endocervical adenocarcinomas
por: Du, Xiuzhen, et al.
Publicado: (2022)

CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer
por: Hu, Pan, et al.
Publicado: (2023)

Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival
por: Eftang, Lars L, et al.
Publicado: (2013)

Role of LATS1/2 in Prognosis of Advanced Gastric Cancer and Its Relationship With the Tumor Immune Microenvironment
por: Guo, Yixian, et al.
Publicado: (2020)

The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells
por: Lu, Yan, et al.
Publicado: (2021)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mfg96nslrlo32m41kc8qjk0e1m